RESEARCH

Photo courtesy of the Northwestern Medicine Chicago Proton Center

Registry Study

Breast Trials

Lung Trials

Prostate Trials

Pancreas Trials

BREAST TRIALS

BRE009-23

Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO)

The Primary objective is to determine if the 2-year rate of grade ≥3 treatment-related skin and soft tissue toxicities using Hypofractionated proton therapy is non-inferior to conventionally-fractionated proton radiotherapy.

BRE008-12

Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation

The purpose of this study is to look at the rates of acute and long term adverse events of postoperative proton radiotherapy for complex loco-regional irradiation in women with loco-regionally advanced breast cancer. This study specifically includes longitudinal follow up to assess the incidence of cardiac mortality and second malignant neoplasms at 10 and 15 years following proton therapy.

BRE007-12

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The primary objective of this study is to determine freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at 3 years.

LUNG TRIALS

LUN005-12

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

PROSTATE TRIALS

GU010-18

Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

The purpose of this study is to see what effects image-guided proton based radiation therapy, and/or conventional radiation therapy and hormonal therapy (if high risk nodal involvement), has on prostate cancer that has the risk of returning or that has already returned.

GU003-10

Phase III Study of Mildly Hypo-fractionated Image Guided Proton Beam Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

This study is for patients who have been staged with intermediate risk prostate cancer. In this study all patients will receive a mildly hypo-fractionated dose of radiation (28 treatment days). Patients in group 1 will receive additional androgen deprivation therapy, patients in group 2 will not receive additional treatment.

GU002-10

A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate

This study is for patients who have been staged with low risk prostate cancer. The study is comparing the good and bad effects of 5 treatments (hypo-fractionation) of proton radiation to 44 treatments (standard-fractionation) of proton radiation.

PANCREAS TRIALS

PAN009-18

A Phase III Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma

The purpose of this study is to see what effects proton radiation combined with capecitabine and surgery (if performed) has on pancreatic cancer. The goal is to improve disease-free survival, increase the share of marginally resectable and unresectable patients being converted to resectable, and to look at the side effects from the treatment and how the tumor responds to the combination of treatment with proton radiation.

REGISTRY STUDY

REG001-09

Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Proton Therapy

The tracking program allows the collection and analysis of patient information to evaluate the disease process and treatment related outcomes thus defining strengths and weaknesses of our program ultimately leading to better patient care. The Evaluation Tracking Program (ETP) consists of prospective enrollment and collection of information from the date of the ETP approval and patient consent.

DATA USE REQUESTS

Please review the Data Use and Publication
 Policy before submitting a data usage request.
MEMBERSHIP PER TRIAL/PROTOCOL

YOU CHOOSE TO
PARTICIPATE

MEMBERSHIPS PER TRIAL/PROTOCOL

YOU CHOOSE TO
PARTICIPATE